Metraipolis › archive › dc_10ea3ad5b2f7

Empagliflozin and Cardiovascular Outcomes: A Systematic Review of Randomized Controlled Trials in Populations With Diabetes and Heart Failure — Europe PMC PMID:40955256

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40955256
DOI
10.7759/cureus.90150
License (as archived)
solo-consultazione
Archived
2026-11-10T14:17:43.467Z
SHA-256 of the archived text
cb04ef90030cee17e1ee76d917e7d7f7e41fc34d963eeb31e0de6700027472c4
Stable URL of this page
https://metraipolis.com/documento/dc_10ea3ad5b2f7

How to cite

Empagliflozin and Cardiovascular Outcomes: A Systematic Review of Randomized Controlled Trials in Populations With Diabetes and Heart Failure — Europe PMC PMID:40955256 — Europe PMC (en), https://europepmc.org/article/MED/40955256 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_10ea3ad5b2f7 (Metraipolis archive dc_10ea3ad5b2f7, sha256 cb04ef90030cee17e1ee76d917e7d7f7e41fc34d963eeb31e0de6700027472c4)
BibTeX
@misc{dc10ea3ad5b2f7,
  title = {Empagliflozin and Cardiovascular Outcomes: A Systematic Review of Randomized Controlled Trials in Populations With Diabetes and Heart Failure — Europe PMC PMID:40955256},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40955256},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_10ea3ad5b2f7; sha256 cb04ef90030cee17e1ee76d917e7d7f7e41fc34d963eeb31e0de6700027472c4},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40955256. Agents can read the archived copy with the MCP tool read_document.